JAB-BX467 / Jacobio Pharma - LARVOL DELTA

Pipeline Highlights: JAB-BX467 (HER2-STING iADC) (Jacobio Press Release) - "An IND submission is expected in the second half of 2026."

IND • Oncology

JAB-BX467 (HER2-STING iADC) (PRNewswire) - "Currently in IND-enabling stage, with IND filing planned for H2 2026."

IND • Solid Tumor

Jacobio Pharma Announces 2024 Annual Results (PRNewswire) - "JAB-BX467: The IND application is being planned to be submitted in 2026."

IND • Oncology